Immix Biopharma Announces Pricing of $125 Million Underwritten Offering of Common Stock

The planned share sale would dilute existing holders if it closes, while net proceeds are intended partly for NXC-201 development.

Rhea-AI Summary

Immix Biopharma (IMMX) priced an underwritten common-stock offering expected to generate $125 million in gross proceeds.

The offering covers 11,363,637 shares at $11.00 each. It is expected to close on or about September 30, 2026, subject to customary closing conditions. Gross proceeds are before underwriting discounts, commissions and offering expenses payable by Immix. The company intends to use net proceeds for NXC-201 development, working capital and general corporate purposes. New and existing institutional investors participated.

3 points · 1 major

MixediHow this balance works

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance worksHow Sentiment works

1 major · 2 points

Hollow bars mark forward-looking points. How the balance works

Positive

• Major point. Forward-looking: it has not happened yet and may not happen.$125 million in gross proceeds is expected from the priced offering. 15% of market cap
• Minor point. Forward-looking: it has not happened yet and may not happen.Net proceeds are intended partly to fund NXC-201 development.
• Minor pointNew and existing institutional investors participated in the offering.

Negative

• Major point. Forward-looking: it has not happened yet and may not happen.11,363,637 new common shares at $11.00 each would dilute existing holders if issued.
• Minor point. Forward-looking: it has not happened yet and may not happen.Underwriting discounts, commissions and offering expenses will reduce net proceeds below expected gross proceeds.

News Explained

The deal is priced but still awaiting its expected close: Immix is selling 11,363,637 new common shares for company proceeds; if issued, the added shares increase the share count and reduce existing holders’ percentage ownership.

Argus 15 min delay 16 alerts

-4.10% vs previous close $11.00 last price 229.3x rel. volume Open Argus

Details

Market move: IMMX -4.10% vs previous close. underwritten offering

+9.0% Peak Tracked

-9.9% Trough Tracked

$9.92 – $12.84 Day Range

$786.93M Market Cap

On Sep 29, the day this news came out, the latest delayed price for IMMX is 4.10% below the previous close. Argus tracked a peak move of +9.0% during the session. Argus tracked a trough of -9.9% from its starting point during tracking. Our momentum scanner has recorded 16 alerts for this stock so far that day. The latest delayed price is $11.00. Relative volume is exceptionally heavy at 229.3x the average.

Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.

Market Context

The active S-3 shelf had two recorded prior usages, including a May 21, 2026 424B5; this documents r...

Analysis

The active S-3 shelf had two recorded prior usages, including a May 21, 2026 424B5; this documents repeated use of the same registration mechanism, not remaining capacity.

Key Figures

Shares offered: 11,363,637 shares Public offering price: $11.00 per share Expected gross proceeds: $125 million +1 more

Shares offered

11,363,637 shares

Underwritten registered offering

Public offering price

$11.00 per share

Common stock offering

Expected gross proceeds

$125 million

Before underwriting discounts, commissions, and offering expenses

Expected closing

On or about September 30, 2026

Subject to customary closing conditions

Previous Offering Reports

4 past events · Latest: May 22

Same Type 4 events

1. May 22

   Offering closing

   24h Move

   +0.7%

   Closed a $150 million offering, selling 16,778,524 shares at $8.94.

2. May 21

   Offering pricing

   24h Move

   -3.0%

   Priced 16,778,524 shares at $8.94 for expected gross proceeds of $150 million.

3. Dec 09

   Offering closing

   24h Move

   +2.0%

   Closed an offering of common shares and pre-funded warrants with approximately $93.7 million net proceeds.

4. Dec 07

   Offering pricing

   24h Move

   +10.6%

   Priced common shares and pre-funded warrants for expected gross proceeds of $100 million.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

underwritten offering, shelf registration statement, form s-3, prospectus supplement

4 terms

underwritten offering financial

"pricing of an underwritten registered offering"

An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.

shelf registration statement regulatory

"pursuant to a shelf registration statement on Form S-3"

A shelf registration statement is a document a company files with regulators that allows it to sell shares or bonds quickly when it’s a good time to raise money. It’s like having a pre-approved plan ready so the company can act fast without going through lengthy paperwork each time they want to sell, making fundraising more flexible.

form s-3 regulatory

"shelf registration statement on Form S-3"

Form S-3 is a legal document companies use to register their stock sales with the government, making it easier and faster for them to raise money by selling shares to investors. It’s like having a pre-approved shopping list that lets a company quickly sell new shares when they need funds, without going through a lengthy approval process each time.

prospectus supplement regulatory

"A prospectus supplement and accompanying prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

LOS ANGELES, Sept. 29, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “we” or “us” or “IMMX”), a global leader in relapsed/refractory AL Amyloidosis, today announced the pricing of an underwritten registered offering of 11,363,637 shares of its common stock at a public offering price of $11.00 per share. The gross proceeds from this offering are expected to be $125 million, before deducting underwriting discounts and commissions and offering expenses payable by the Company. The offering is expected to close on or about September 30, 2026, subject to the satisfaction of customary closing conditions.

Immix intends to use the net proceeds from this offering to fund NXC-201 development, working capital and general corporate purposes.

J.P. Morgan is acting as the sole book-running manager for the offering. The offering included participation from new and existing institutional investors, including Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments L.P., Wellington Management and other leading U.S. biotechnology institutional investors and mutual funds.

The shares of common stock described above are being offered and sold by the Company pursuant to a shelf registration statement on Form S-3 (File No. 333-292665), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 9, 2026, and declared effective on January 22, 2026. A prospectus supplement and accompanying prospectus describing the terms of the offering will be filed with the SEC and will be available on the SEC’s website located at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus related to this offering, when available, may be obtained from J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Immix Biopharma, Inc.

Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a proprietary CD3ζ, CD8 hinge and binder “digital filter” designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the federal securities laws. Words such as “may,” “might,” “will,” “should,” “believe,” “expect,” “anticipate,” “estimate,” “continue,” “predict,” “forecast,” “project,” “plan,” “intend” or similar expressions, or statements regarding intent, belief, or current expectations, are forward-looking statements. These forward-looking statements are based upon current estimates and assumptions and include statements relating to the offering, including the timing of the closing of the offering, the anticipated use of proceeds therefrom, the potential benefits of the Company’s product candidate CAR-T NXC-201 and the timing and results related to clinical trials, including planned trials. While the Company believes these forward-looking statements are reasonable, undue reliance should not be placed on any such forward-looking statements, which are based on information available to us on the date of this release. These forward-looking statements are subject to various risks and uncertainties, many of which are difficult to predict that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from current expectations include, among others, risks and uncertainties relating to market conditions; the completion of the proposed offering on the anticipated terms or at all; the risk that the estimates for the number of patients in the U.S. with relapsed/refractory AL Amyloidosis and the market size are not accurate; the risk that further data from the ongoing Phase 1/2 clinical trials for NXC-201  will not be favorably consistent with the data readouts to date; that no drug product developed by the Company has received FDA pre-market approval or otherwise been incorporated into a commercial drug product; that success in early phases of pre-clinical and clinicals trials do not ensure later clinical trials will be successful; and those other risks disclosed in the section “Risk Factors” included in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025 and other periodic or current reports subsequently filed with the Securities and Exchange Commission. These reports are available at www.sec.gov. Immix Biopharma cautions that the foregoing list of important factors is not complete. Immix Biopharma cautions readers not to place undue reliance on any forward-looking statements. Immix Biopharma does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law. If we update one or more forward-looking statements, no inference should be drawn that we will make additional updates with respect to those or other forward-looking statements.

Contacts:

Mike Moyer
LifeSci Advisors
mmoyer@lifesciadvisors.com

Company Contact
irteam@immixbio.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many shares is Immix Biopharma offering, and at what price?

Immix Biopharma is offering 11,363,637 common shares at a public offering price of $11.00 per share. Gross proceeds are expected to be $125 million before underwriting discounts, commissions and offering expenses payable by the company.

Which institutional investors participated in Immix Biopharma's offering?

Participants included Eventide Asset Management, Janus Henderson Investors, Ridgeback Capital Investments L.P. and Wellington Management, along with other U.S. biotechnology institutional investors and mutual funds.